NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for pacritinib (VONJO)1*

INDICATION2: VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera [PPV] or 
post-essential thrombocythemia [PET]) MF with a platelet count below 50 x 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

The NCCN Category 2a/2b recommendations below fall outside the pacritinib (VONJO) US prescribing information

Pacritinib (VONJO) is a recommended option in both first- and second-line by NCCN Guidelines®.1*†

Lower-Risk MF: Platelets <50 x 109/L
Higher-Risk MF: Platelets <50 x 109/L and ≥50 x 109/L
MF-associated anemia
  • First-line treatment option if symptomatic† MF with platelets <50 x 109/L; second-line treatment option if symptomatic† MF with platelets <50 x 109/L and have intolerance, no response, or loss of response to initial treatment (Category 2A)

 

  • First-line treatment option in patients with platelets <50 x 109/L who are not candidates for transplant or for whom transplant is not currently feasible (Category 1, preferred)
  • First-line treatment option if symptomatic† MF with platelets ≥50 x 109/L who are not candidates for transplant or for whom transplant is not currently feasible; second-line treatment option if symptomatic† MF with platelets ≥50 x 109/L; are not candidates for transplant or for whom transplant is not currently feasible; and have intolerance, no response, or loss of response to initial treatment (Category 2B)

 

  • Treatment option for patients with MF-associated anemia who have no splenomegaly or constitutional symptoms (Category 2B, other recommended regimen)
  • Treatment option for patients with MF-associated anemia with ongoing symptomatic splenomegaly and/or constitutional symptoms (Category 2A, other recommended regimen)
  • Change to pacritinib as a treatment option in patients with MF-associated anemia with splenomegaly and constitutional symptoms well-controlled on current JAK inhibitor (Category 2A, useful in certain circumstances)
  • *See the NCCN Guidelines for detailed recommendations, including other options.
  • †Symptomatic/symptoms=symptomatic splenomegaly and/or constitutional symptoms.
  • NCCN=National Comprehensive Cancer Network® (NCCN®).
  • References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 12, 2025. To view the most recent and complete versions of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 2. VONJO. Prescribing information. Sobi, Inc.; 2025.